Quick Answer
Xilio Therapeutics, Inc. reported Stockholders Equity of $35.27 million for fiscal year 2025.
Xilio Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $35.27M | +100.4% |
| 2024 | $17.60M | -52.2% |
| 2023 | $36.83M | -65.1% |
| 2022 | $105.65M | -43.0% |
| 2021 | $185.43M | +322.6% |
| 2020 | -$83.29M | -182.1% |
| 2019 | -$29.52M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$8.10M | -138.6% | -214.5% |
| June 30, 2025 | $7.07M | -78.8% | -33.9% |
| March 31, 2025 | $10.70M | -58.5% | -39.2% |
| December 31, 2024 | $17.60M | -52.2% | -16.1% |
| September 30, 2024 | $20.97M | -60.0% | -37.2% |
| June 30, 2024 | $33.42M | -50.4% | +29.7% |
| March 31, 2024 | $25.77M | -69.6% | -30.0% |
| December 31, 2023 | $36.83M | -65.1% | -29.9% |
- Xilio Therapeutics, Inc. showed an increase of +100.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Xilio Therapeutics, Inc.’s stockholders equity has grown by 219.5% (from -$29.52 million to $35.27 million).
- The most recent figure is from Xilio Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: